Company Overview and News
Futures pointed to a strong start for Hong Kong’s stock market on Monday morning after technology shares pushed US markets to record closing highs on Friday.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Chinese private school operator YuHua Education is to launch an up to HK$1.9 billion initial public offering (IPO) in Hong Kong in February.
Foreign operators are limited to running kindergartens and upper secondary schools, not primary or lower secondary schools, Shanghai’s education commission said
Three mainland private education providers are seeking listings as the “sunrise” industry defies the economic slowdown
China Maple Leaf Educational Systems, the mainland’s largest international schools operator, appears to have successfully calmed broker nerves, after its shares lost more than a fifth of their value in two days.
China Maple Leaf Educational Systems could take an earnings hit this year with its acquisition of Singapore’s Lucrum Development, despite the optimistic market outlook for China’s leading international school operator.
The country hosts the largest number of international schools in the world, and analysts say it will need at least 1,000 more in coming years
The director activity rose based on filings on the stock exchange in the second week of May with 39 companies that recorded 191 purchases worth HK$360 million versus 12 firms with 51 disposals worth HK$54 million. The buy figures were sharply up from the previous week’s four-day total of 29 companies, 158 purchases and HK$238 million. On the selling side, the number of firms and trades were up from the previous week’s nine companies and 25 disposals.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...